The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca
Consulting or Advisory Role - Agendia; AstraZeneca; Lilly; MSD; Novartis; Roche/Genentech; Seagen
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).
 
Virginia G. Kaklamani
Honoraria - AstraZeneca; daichi; Genentech; Genomic Health; Gilead Sciences; Novartis; Pfizer; Puma Biotechnology; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; Athenex; bioTheranostics; Celldex; Eisai; Puma Biotechnology
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Genentech; Genomic Health; Novartis; Pfizer; Puma Biotechnology
Research Funding - Eisai
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Philippe Georges Aftimos
Honoraria - Gilead Sciences; Roche; Synthon
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; Deloitte; G1 Therapeutics; Gilead Sciences; Macrogenics; Menarini; Novartis; Novartis; Radius Health; Roche; Servier
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pfizer; Roche Belgium
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
Janice M. Lu
Honoraria - AstraZeneca/Daiichi Sankyo; Lilly; Pfizer; Sanofi/Aventis; Seagen
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Novartis; Pfizer; Sanofi/Aventis
Research Funding - Ambrx (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Radius Health (Inst)
 
Patrick Neven
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Guillermo Streich
No Relationships to Disclose
 
Alberto J. Montero
Honoraria - AstraZeneca; Celgene; OncoSec
Consulting or Advisory Role - New Century Health; Welwaze
(OPTIONAL) Uncompensated Relationships - Roche
 
Frederic Forget
Travel, Accommodations, Expenses - ipsen; Teva
 
Marie-Ange Mouret-Reynier
No Relationships to Disclose
 
Joohyuk Sohn
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - Roche
 
Donatienne Taylor
No Relationships to Disclose
 
Kathleen Kiernan Harnden
Honoraria - E-Health Now
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
 
Hung T. Khong
Stock and Other Ownership Interests - agenus; Lipocine; MEI Pharma; MustangBio; TG Therapeutics; Tiziana Life Sciences; Vaxart
Consulting or Advisory Role - Celcuity
Research Funding - AstraZeneca
 
Judit Kocsis
No Relationships to Disclose
 
Florence Dalenc
No Relationships to Disclose
 
Patrick Michael Dillon
Research Funding - Abbvie (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Tesaro (Inst); Tolero Pharmaceuticals (Inst)
 
Giulia Tonini
No Relationships to Disclose
 
Kris Grzegorzewski
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Novartis
 
François-Clement Bidard
Consulting or Advisory Role - AstraZeneca; Lilly; Menarini; Novartis; Pfizer; Radius Health; Sanofi (Inst)
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Rain Therapeutics; Roche
Research Funding - Menarini Silicon Biosystems (Inst); Novartis (Inst); Pfizer (Inst); Prolynx (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche